Relative and Absolute Changes of Activated Platelets, Microparticles and Platelet Aggregates after Activation in vitro

Matzdorff, Axel; Berchner, D.; Kühnel, Gitta; Kemkes‐Matthes, B.; Pralle, H.; Voss, Reinhard

doi:10.1159/000022444

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDMAs were detected in another appropriate gate corresponding to the 5% of events recruited in the higher part of the area belonging to platelets according to other authors [33,34] . Within these acquisition gates, PDMPs and PDMAs were identified as CD61-positive events.…”

Section: Methodsmentioning

confidence: 99%

Platelet Activation and Red Blood Cell Phosphatidylserine Exposure Evaluated by Flow Cytometry in Patients with Behçet’s Disease: Are They Related to Thrombotic Events?

Martı́nez

Ricart

Ruiz-Aja

et al. 2007

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Behçet’s disease (BD) is associated with an increased risk of venous and arterial thromboses that are associated with morbidity and mortality increase, although the mechanisms are not well established. In the present study, we used whole blood cytometry to determine the exposure of CD62 on the surface of platelets and the expression of phosphatidylserine (PS) on the surface of circulating red blood cells. Microparticle and microaggregate formation from platelets were also determined in a well-classified group of 72 patients (39 males, 33 females, aged 46.5 ± 12.5 years) with BD, in comparison with a well-matched control group of 72 healthy volunteers. Results showed no differences in the above-mentioned parameters when BD patients and controls were compared. However, when we compared BD patients with/without thrombosis using these parameters, there were significant differences between both groups. BD patients with previous thrombosis had a higher percentage of circulating CD62-positive platelets and a higher number of circulating microaggregates than those without thrombosis, suggesting that platelet activation may be involved in the development of thrombotic events in these patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Platelet Activation and Red Blood Cell Phosphatidylserine Exposure Evaluated by Flow Cytometry in Patients with Behçet’s Disease: Are They Related to Thrombotic Events?

Martı́nez

Ricart

Ruiz-Aja

et al. 2007

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…Matzdorff et al (23) examined activation of platelets in vitro. The labeled MPs were used to assess the absolute number of platelets.…”

Section: Discussionmentioning

confidence: 99%

Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation

Loudová

Krejsek

2003

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

We evaluated expression of platelet activation markers in blood samples of 15 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) by flow cytometry. Analysis was performed before the beginning of PTCA, during initial coronary angiography and after the end of PTCA or after a stent placement, respectively. We evaluated platelet-derived microparticles, platelet-leukocyte aggregates, platelet aggregates and a membrane expression of CD62P and CD63 molecules. Responsiveness of platelets to the activationin vitrowith thrombin-receptor activating protein – 6 (TRAP-6) was tested simultaneously. Statistically significant differences between patient samples were found only in the expression of the activation markers CD62P (before PTCA 0.22 %, during 0.39 %, after 0.67 %), CD63 (0.26 %/ 0.45 %/ 0.85 %) and platelet-leukocyte aggregates (13.57 %/ 18.39 %/ 23.63 %).In the same group the expression of all constitutive membrane markers was statistically significantly decreased: in patients undergoing PTCA was the expression of CD9:87.98 % (in comparison with control group 94.98 %), CD31: 87.10 % (92.78 %), CD36: 87.37 % (90.98 %), CD41: 88.09 % (95.62 %), CD42a: 88.54 % (94.98 %), CD42a: 88.31 % (94.13 %).

show abstract

“…Some groups had to collect blood directly from the coronary sinus to detect any activated platelets [27,48]. We could show in stirred whole blood samples in vitro that low doses of platelet agonists induce profound platelet aggregation while the number of CD62p-positive platelets did not increase [49]. The most likely explanation is that all activated and CD62p-positive platelets become incorporated into the platelet thrombus.…”

Section: Limitations To the Flow-cytometric Detection Of Platelet Actmentioning

confidence: 97%

Evaluation of Platelet Activation in Coronary Artery Disease – the Role of Flow Cytometry

Matzdorff¹

2000

Transfus Med Hemother

Self Cite

View full text Add to dashboard Cite

Within the last decade flow cytometry gave many new insights into the physiology and pathophysiology of platelet activation. This review provides an overview of the different flow-cytometric techniques which have been applied to study platelet activation in patients with coronary artery disease. CD62p is probably the most commonly used platelet activation marker in patients with coronary artery disease. Other antibodies (PAC 1, LIBS1, anti-FGN, etc.) can be utilized to monitor activation of the glycoprotein (GP) IIb/IIIa receptor. The analysis of microparticles, platelet-leukocyte conjugates, and intraplatelet signaling cascades provides additional information on the different steps of platelet activation. However, activation markers do not always adequately reflect the degree of platelet activation. Limitations of flow-cytometric techniques will be discussed. Flow cytometry shows that GP IIb/IIIa activation plays a pivotal role in coronary artery thrombosis which supports the development of GP IIb/IIIa receptor blockers to treat acute coronary syndromes. The GP IIb/IIIa-receptor occupancy assay is one of the first flow-cytometric platelet assays designed to become a part of routine hematology analysis. Flow-cytometric techniques contribute substantially to our understanding of platelet activation during acute coronary syndromes and thus to the development of new drugs and therapeutic approaches.

show abstract

Relative and Absolute Changes of Activated Platelets, Microparticles and Platelet Aggregates after Activation in vitro

Cited by 9 publications

References 23 publications

Platelet Activation and Red Blood Cell Phosphatidylserine Exposure Evaluated by Flow Cytometry in Patients with Behçet’s Disease: Are They Related to Thrombotic Events?

Platelet Activation and Red Blood Cell Phosphatidylserine Exposure Evaluated by Flow Cytometry in Patients with Behçet’s Disease: Are They Related to Thrombotic Events?

Platelets Activation in Patients Undergoing PTCA and Their Responsiveness After in vitro Stimulation

Evaluation of Platelet Activation in Coronary Artery Disease – the Role of Flow Cytometry

Contact Info

Product

Resources

About